Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultralife (ULBI) Research & Development (2016 - 2025)

Ultralife (ULBI) has 15 years of Research & Development data on record, last reported at $2.9 million in Q3 2025.

  • For Q3 2025, Research & Development rose 35.89% year-over-year to $2.9 million; the TTM value through Sep 2025 reached $10.0 million, up 29.65%, while the annual FY2024 figure was $8.3 million, 9.79% up from the prior year.
  • Research & Development reached $2.9 million in Q3 2025 per ULBI's latest filing, up from $2.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $2.9 million in Q3 2025 and bottomed at $1.6 million in Q1 2021.
  • Average Research & Development over 4 years is $2.1 million, with a median of $2.0 million recorded in 2023.
  • Peak YoY movement for Research & Development: fell 13.58% in 2024, then surged 36.9% in 2025.
  • A 4-year view of Research & Development shows it stood at $1.6 million in 2021, then rose by 12.45% to $1.9 million in 2023, then surged by 30.35% to $2.4 million in 2024, then increased by 18.27% to $2.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $2.9 million in Q3 2025, $2.3 million in Q2 2025, and $2.4 million in Q1 2025.